LIN-MD-63: A Multicenter Randomized Double-blind Placebo-controlled Parallel-group Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7 to 17 Years With Irritable Bowel Syndrome With Constipation (IBS-C) (ie Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to find out if the drug (Linaclotide) works and is safe to treat irritable bowel syndrome with constipation (IBS-C) in children as it is in adults.
Description
The purpose of this study is to find out if the drug (Linaclotide) works and is safe to treat irritable bowel syndrome with constipation (IBS-C) in children as it is in adults.
Details
| Condition | irritable bowel syndrome,constipation |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX6763 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.